Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections sits in the top decile of US sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count).
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections: 45 sponsored US clinical trials, 2 recruiting.
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections sponsors 45 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 38 completed. 10 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 8 trials.
Top-decile sponsor footprint
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections ranks in the top decile of sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
38 of 42 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
45 total, page 1 of 1
Menopausal HT for Women Living With HIV (HoT)
NCT06856174
Observational PIC Destination Cohort
NCT05985642
Consent for Use of Stored Patient Specimens for Future Testing
NCT00031408
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide
NCT04636437
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
NCT04042740
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
NCT03819114
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
NCT03512210
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
NCT03070223
Biomarkers to Predict Time to Plasma HIV RNA Rebound
NCT03001128
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
NCT02706717
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
NCT02605304
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
NCT02440789
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
NCT02582684
Sitagliptin for Reducing Inflammation and Immune Activation
NCT02513771
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
NCT01903031
Modulation of Immune Activation by Aspirin
NCT02155985
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
NCT01969058
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
NCT02128217
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
NCT01928927
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
NCT01777997
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
NCT01400412
Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
NCT01426438
Sevelamer for Reducing Endotoxemia and Immune Activation
NCT01543958
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
NCT01403051
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
NCT01466595
Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women
NCT01296152
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
NCT01351025
Telephone Support to Improve Adherence to Anti-HIV Medications
NCT00988442
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
NCT01029249
Durability of Adherence in Self-Management of HIV
NCT00991302
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
NCT00959413
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
NCT00851799
Comparative Study of Three NNRTI-Sparing HAART Regimens
NCT00811954
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
NCT00830804
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
NCT00665353
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
NCT00819390
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
NCT00709111
HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
NCT00442962
Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
NCT00361257
Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis
NCT00108862
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
NCT00118898
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
NCT00084136
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
NCT00090779
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
NCT00001137
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 24 |
| Phase 3 | 3 |
| Phase 4 | 7 |
Therapeutic Areas
What is open in the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections pipeline
2 recruiting of 45 indexed (4% open); 38 completed (84%).
Phase mix: 10 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: HIV-1-infection (8 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections: open-pipeline peers nationwide
Peers matched on 45 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 45 trials (± recruiting share)
- AIDS Malignancy Consortium · 45 trials · 11% recruiting
- Cambridge Health Alliance · 45 trials · 16% recruiting
- Carilion Clinic · 45 trials · 20% recruiting
- Genmab · 45 trials · 24% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Galderma R&D · 4% recruiting · 158 trials
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
Related
What to do with this Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections page
45 registered trials is a research-attention snapshot, not an endorsement of Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections or any single study.
- 2 of Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV-1-infection is the condition Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections pipeline card: 45 registered trials from official public datasets.Report a data error.